DIN/PIN Detail - 02282097

920000   MISCELLANEOUS THERAPEUTIC AGENTS
923600   DISEASE-MODIFYING ANTIRHEUMATIC AGENTS

ORENCIA 250 MG / VIAL INJECTION

(ABATACEPT)

Manufacturer:
BRISTOL-MYERS SQUIBB
ECDET Review Status/Past Decision(s):

 2010/04/01 - Special Authorization Criteria Change - Rheumatoid Arthritis

CDR Status/Past Decision(s):

 2014/10/01 - Special Authorization Criteria Change - Polyarticular Juvenile Idiopathic Arthritis


 2013/11/01 - Special Authorization Criteria Change - Rheumatoid Arthritis


 2011/05/01 - Special Authorization Criteria Change - Juvenile Idiopathic Arthritis


 2011/02/01 - Special Authorization Criteria Change - Juvenile Idiopathic Arthritis


 2010/09/01 - Special Authorization Criteria Change - Rheumatoid Arthritis


 CDR - List in a similar manner


 2010/04/01 - Special Authorization - Juvenile Idiopathic Arthritis


 2009/10/01 - Under Review


 2009/10/01 - Special Authorization Criteria Change - Rheumatoid Arthritis


 CDR - List with criteria/condition


 2009/03/04 - Special Authorization Criteria Change - Rheumatoid Arthritis


 2008/10/01 - Special Authorization


 2008/07/01 - Under Review


 2008/04/01 - Under Review


 2008/01/01 - Under Review


 CDR - List with criteria/condition


To return to the printable Drug Benefit List and related publications, click here.

Last Updated: null

NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.

Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.